Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Biosimilars for the Treatment of Patients with Psoriasis: A Consensus Statement from the Biosimilar Working group of the International Psoriasis Council

As biosimilars have become available in various parts of the world, the International Psoriasis Council (IPC) had reviewed aspects of their use.

To provide consensus statements from the Biosimilar Working Group (BSWG) about the use of biosimilars in patients with psoriasis.

A semi-qualitative structured process to approve consensus statements on biosimilars, using the nominal group technique. The final statements were validated by a survey of the paricipants. Approval of the consensus statements was pre-defined as >80% positive opinion.

Consensus was reached in 36/38 statements regarding regulatory considerations, extrapolation of indication, interchangeability, substitution at the pharmacy level, pharmacovigilance, traceability, naming, biosimilar policy, education, and cost of biosimilars. Examples statements include : “Switching a stable patient from a reference product to a biosimilar product is appropriate if the patient and physician agree to do so” and “Patients and patients’ organisations should be involved in all decision making and policy development about the use of biosimilars”.

The IPC BSWG provides consensus statements for the use of biosimilars in the treatment of patients with psoriasis. We suggest that these statements provide global guidance to clinicians, healthcare organisations, pharmaceutical companies, regulators and patients, regarding the development and use of biosimilars in psoriasis.

Link to article.

Arnon D. Cohen, Ronald Vender, Luigi Naldi, Robert E. Kalb, Tiago Torres, Murlidhar Rajagopalan, Joelle van der Walt, Lluís Puig, Helen S. Young. JAAD International. 2020 Sept 25. doi: 10.1016/j.jdin.2020.09.006.


Filter by Topic:

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.